Flow-through Plasma circuit pathogen reduction device for patients with sepsis and/or liver failure

点击翻译按钮获取中文摘要

Sepsis, overwhelming microbial infection of the bloodstream, is a potentially fatal condition. Antibiotics are the mainstay of treatment, but cannot cope with overwhelming sepsis, and as resistant bacteria develop, antibiotics will become progressively less effective. Sepsis is also one of the key reasons for patient demise in liver failure. Today, with ever increasing antibiotic resistance, new approaches are urgently required to combat sepsis from any aetiology. A flow-through pathogen reduction module (PRT) for use in intensive care units would be a major breakthrough for intensive care medicine. A meaningful reduction of plasma microbes would enable conventional antimicrobial treatments to be effective once more, and would deliver benefit to patients worldwide. The project will address this need. Building on a well-developed, innovative concept developed by UCL it will design, manufacture, demonstrate and test (using in vitro models) a human scale prototype. The work will generate new protectable IP for the partners, and enable them to develop and derisk business plans for the development and roll-out of a commercial grade device, building on input from relevant clinical and commercial stakeholders.